Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.…
Arecor Therapeutics plc (LSE:AREC): FTSE AIM All-Share Small Cap Growth Stock — Insulin Technology and Funding Keep Small Cap Growth Stock in Focus
Arecor Therapeutics (LON: AREC) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 71.50 GBp on 20 November 2026, down 3.4% over 52 weeks. Its 52-week range is 55.27 GBp to 95.00 GBp: the price is 24.7% below the high and 29.4% above the low.
At a market capitalisation of 32.39M GBP, it trades at 71.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 116% for AREC.
Arecor Therapeutics reports return on equity of 10.3% and revenue down 80.9% year over year.
It holds more cash than debt, a net cash position of 3.10M GBP. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock; their mean price target of 250.50 GBp is 250.3% above the current price.
No upcoming events tracked.